AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 217 filers reported holding AMICUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $19,576,000 | -0.6% | 1,875,105 | +2.3% | 0.75% | -4.5% |
| Q2 2022 | $19,691,000 | +20.9% | 1,833,446 | +6.6% | 0.78% | +44.7% |
| Q1 2022 | $16,284,000 | -17.6% | 1,719,577 | +0.5% | 0.54% | -8.6% |
| Q4 2021 | $19,770,000 | +20.7% | 1,711,710 | -0.2% | 0.59% | +17.0% |
| Q3 2021 | $16,376,000 | -4.7% | 1,714,731 | -3.8% | 0.51% | -1.0% |
| Q2 2021 | $17,175,000 | +2.7% | 1,781,625 | +5.3% | 0.51% | -5.0% |
| Q1 2021 | $16,719,000 | -67.1% | 1,692,241 | -23.2% | 0.54% | -68.1% |
| Q4 2020 | $50,894,000 | +91.3% | 2,204,140 | +17.0% | 1.68% | +45.9% |
| Q3 2020 | $26,604,000 | -4.2% | 1,884,144 | +2.3% | 1.16% | -7.2% |
| Q2 2020 | $27,768,000 | +46.8% | 1,841,376 | -10.0% | 1.24% | +15.2% |
| Q1 2020 | $18,912,000 | +51.5% | 2,046,778 | +59.7% | 1.08% | +100.6% |
| Q4 2019 | $12,482,000 | – | 1,281,553 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |